(Q37058011)

18 August 2017

1 reference

title

Sorafenib: in hepatocellular carcinoma (English)

1 reference

18 August 2017

2

Gillian M Keating

1 reference

18 August 2017

Dene Simpson

1

1 reference

18 August 2017

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

68

1 reference

18 August 2017

251-258

1 reference

18 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200868020-00007

18 August 2017

0 references

cites work

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868020-00007

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

12 December 2020

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

1 reference

12 December 2020

Sorafenib: in advanced renal cancer

1 reference

12 December 2020

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

12 December 2020

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

12 December 2020

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.

1 reference

12 December 2020

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

12 December 2020

Emerging drugs for hepatocellular carcinoma.

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

12 December 2020

10.2165/00003495-200868020-00007

Identifiers

DOI

1 reference

PubMed ID

18197728

Dimensions Publication ID

18 August 2017

0 references

1 reference

PubMed ID

18197728